Az élelmiszer-ipari adalékanyagok által kiváltott tünetek

MatarkaID=217619

A táplálekallergiás fogyasztók táplálkozási biztonsága közös ügy

A közlemény a táplálékallergia gyakoriságának, klinikumának, dietoterápiájának és prevenciójának kérdéseit tárgyalja. Sorra veszi azokat a legfontosabb lehetåségeket, amelyek az allergiás betegek biztonságos élelmiszer választását segítik. Megállapítja, hogy – bár az élelmiszer-jelölés a legtöbb ember számára elegendå információt tartalmaz – az allergiás egyénnek nem nyújt teljes köré biztonságot. Az allergén összetevåk jelölése felhívja ugyan a figyelmet arra, hogy az adott allergiában mely élelmiszereket kell mindenképpen elkerülni, arra azonban, hogy mely élelmiszereket fogyaszthatja, csak az allergén komponenseket nem tartalmazó élelmiszerek megbízható nyilvántartása, a Táplálékallergia és Táplálékintolerancia Adatbank és az élelmiszerjelölés együttesen nyújthat kellå biztonságot. The frequency, symptoms, dietotherapy and prevention of food allergies are being discussed in this publication. The most important options are listed, which help the safe selection of foodstuffs in case of allergic patients. Although conventional listings of food ingredients contain sufficient information for most people, they do not guarantee the safety of allergic subjects. The listing of ingredients that may cause an allergic reaction helps the identification of foodstuffs that have to be avoided under all circumstances; however, based on these listings, allergic patients still cannot decide which foodstuffs may be consumed. It can be concluded that only a reliable database listing foodstuffs that do not contain allergic components, the so-called Food Allergy and Food Intolerance Database together with ingredient listings provide sufficient safety

Positive correlation between persistence of medical nutrition therapy and overall survival in patients with head and neck cancer

Background: Several factors can affect overall survival of head and neck cancer (HNC) patients, including characteristics of the cancer disease and response to treatments. However, patients’ nutritional status and the effectiveness of medical nutrition therapy (MNT) can also impact overall survival. The primary goal of our research was to collect real-life data on the use of MNT in HNC patients and to specifically investigate the correlation between survival and the duration of uninterrupted (persistent) nutrition.Method: The data of this retrospective, analytical, cohort study was collected from electronic healthcare records from the Hungarian National Health Insurance Fund Management. Overall, 38,675 HNC patients’ data of the period between 2012 and 2021 was used. We applied multi-step exclusions to identify patient groups accurately and to avoid biasing factors. Statistical analysis was done by the Kaplan-Meier method, log-rank test, and Cox regression analysis.Results: Throughout the investigated period 16,871 (64%) patients received MNT therapy out of 26,253 newly diagnosed patients (≥18 years). In terms of the persistence of MNT, we divided the patients into three groups (1–3; 4–6; ≥7-month duration of MNT). When comparing these groups, we found that patients receiving long-term (≥7 months) MNT had a significantly longer overall survival (p < 0.0001) than those who received MNT for a shorter duration, both in locally advanced and recurrent/metastatic cases.Conclusion: The main outcome of the study is that there is a positive correlation between the persistence of MNT and the overall survival in HNC patients when nutritional intervention lasts several months. It highlights the responsibility of the specialists during the patient journey to use MNT early and to continue its use for as long as it is beneficial to the patients

Malnutrition risk questionnaire combined with body composition measurement in malnutrition screening in inflammatory bowel disease.

The purpose of malnutrition screening is to predict the probability of a worse outcome due to nutritional factors. The Malnutrition Universal Screening Tool (MUST) can be used for screening in inflammatory bowel disease (IBD); however, it does not provide details about body composition. Our aim was to assess the body composition and combine this with the MUST method to screen risk of malnutrition and sarcopenia. A total of 173 IBD outpatients were enrolled in this cross-sectional study. The MUST scale indicated 21.4% of IBD patients to be at risk of malnutrition. A risk of sarcopenia was detected in 27.7%. However, one third of these patients were not considered to be at risk by their MUST score. Furthermore, Crohn's disease (CD) patients had a strongly unfavorable fat-free mass index (FFMI) value compared to ulcerative colitis (UC) patients, and these differences were significant among men (FFMI: 18.62 +/- 2.16 vs 19.85 +/- 2.22, p = 0.02, in CD and UC males, respectively). As sarcopenia is a relevant prognostic factor, the MUST method should be expanded to include body composition analysis to detect more IBD patients at risk of malnutrition and sarcopenia in order to start their nutritional therapy immediately